Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

被引：33
|
作者：
Kosmider, Olivier [1 ]
Passet, Marie [1 ]
Santini, Valeria [2 ]
Platzbecker, Uwe [3 ]
Andrieu, Valerie [4 ]
Zini, Gina [5 ]
Beyne-Rauzy, Odile [6 ]
Guerci, Agnes [7 ]
Masala, Erico [8 ]
Balleari, Enrico [9 ]
Bulycheva, Ekaterina [3 ]
Dreyfus, Francois [10 ]
Fenaux, Pierre [11 ]
Fontenay, Michaela [1 ]
Park, Sophie [12 ]
机构：
[1] Hop Cochin, AP HP, Hematol Biol, Paris, France
[2] Univ Florence, AOU Careggi, Hematol, I-50121 Florence, Italy
[3] Univ Hosp Carl Gustav Dresden, Dresden, Germany
[4] Hop Bichat Claude Bernard, AP HP, Hematol Biol, Paris, France
[5] Univ Cattolica Sacro Cuore, Rome, Italy
[6] Oncopole, IUCT, Toulouse, France
[7] Hop Brabois, Nancy, France
[8] Univ Florence, Florence, Italy
[9] IRCCS AOU San Martino IST Genova, Genoa, Italy
[10] Hop Cochin, Serv Hematol, Paris, France
[11] Hop St Louis, Serv Hematol Seniors, Paris, France
[12] Univ Grenoble Alpes, CHU Grenoble Alpes, Clin Univ Hematol, Grenoble, France
来源：
HAEMATOLOGICA | 2016年 / 101卷 / 07期
关键词：
myelodysplastic syndromes; cytogenetics and molecular genetics; red cells; SURVIVAL; IMPACT; MODEL;
D O I：
10.3324/haematol.2016.142695
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：280 / 283
页数：4
相关论文
共 50 条
  • [1] Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes
    Caballero, Juan Carlos
    Davila, Julio
    Lopez-Pavia, Maria
    Such, Esperanza
    Bernal, Teresa
    Ramos, Fernando
    Calabuig, Marisa
    Sanchez, Jesus Maria Hernandez
    Pomares, Helena
    Barba, Mercedes Sanchez
    Abaigar, Maria
    Gonzalez, Bernardo
    Merchan, Brayan
    Sancho-Tello, Reyes
    Callejas, Marta
    Munoz-Novas, Carolina
    Cervero, Carlos
    Sanz, Guillermo
    Rivas, Jesus Maria Hernandez
    Campelo, Maria Diez
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [2] Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Tsang, Erica
    Leitch, Heather A.
    ANNALS OF HEMATOLOGY, 2016, 95 (01) : 73 - 78
  • [3] Erythropoiesis-stimulating agents in myelodysplastic syndromes
    Hellstrom-Lindberg, Eva
    LEUKEMIA & LYMPHOMA, 2010, 51 (07) : 1155 - 1156
  • [4] Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes
    Smith, Sheila Weiss
    Sato, Masayo
    Gore, Steven D.
    Baer, Maria R.
    Ke, Xuehua
    McNally, Diane
    Davidoff, Amy
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (01): : 15 - 20
  • [5] p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes
    Frisan, Emilie
    Pawlikowska, Patrycja
    Pierre-Eugene, Cecile
    Viallon, Vivian
    Gibault, Laure
    Park, Sophie
    Mayeux, Patrick
    Dreyfus, Francois
    Porteu, Francoise
    Fontenay, Michaela
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11): : 1964 - 1968
  • [6] Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe?
    Steensma, David P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (01) : 3 - 5
  • [7] Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?
    Erica Tsang
    Heather A. Leitch
    Annals of Hematology, 2016, 95 : 73 - 78
  • [8] Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review
    Affentranger, Lucas
    Bohlius, Julia
    Hallal, Mahmoud
    Bonadies, Nicolas
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 136 : 37 - 47
  • [9] Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
    Itzykson, R.
    Thepot, S.
    Beyne-Rauzy, O.
    Ame, S.
    Isnard, F.
    Dreyfus, F.
    Salanoubat, C.
    Taksin, A. L.
    Chelgoum, Y.
    Berthon, C.
    Malfuson, J. V.
    Legros, L.
    Vey, N.
    Turlure, P.
    Gardin, C.
    Boehrer, S.
    Ades, L.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2012, 36 (04) : 397 - 400
  • [10] Supportive Care in Low-Risk Myelodysplastic Syndromes: Role of Erythropoiesis Stimulating Agents (ESAs)
    Cerchione, Claudio
    Alfinito, Fiorella
    Giannini, Benedetta Maria
    Pane, Fabrizio
    Musuraca, Gerardo
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S318 - S318
12345